Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 153

1.

CD8 T cells and mTOR: new concepts and targets for systemic lupus erythematosus.

Fernandez DR, Crow MK.

Lancet. 2018 Mar 24;391(10126):1126-1127. doi: 10.1016/S0140-6736(18)30544-0. Epub 2018 Mar 15. No abstract available.

PMID:
29551336
2.

Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8.

Ah Kioon MD, Tripodo C, Fernandez D, Kirou KA, Spiera RF, Crow MK, Gordon JK, Barrat FJ.

Sci Transl Med. 2018 Jan 10;10(423). pii: eaam8458. doi: 10.1126/scitranslmed.aam8458.

PMID:
29321259
3.

Defective regulation of L1 endogenous retroelements in primary Sjogren's syndrome and systemic lupus erythematosus: Role of methylating enzymes.

Mavragani CP, Nezos A, Sagalovskiy I, Seshan S, Kirou KA, Crow MK.

J Autoimmun. 2018 Mar;88:75-82. doi: 10.1016/j.jaut.2017.10.004. Epub 2017 Oct 23.

PMID:
29074164
4.

MTHFR gene variants and non-MALT lymphoma development in primary Sjogren's syndrome.

Fragkioudaki S, Nezos A, Souliotis VL, Chatziandreou I, Saetta AA, Drakoulis N, Tzioufas AG, Voulgarelis M, Sfikakis PP, Koutsilieris M, Crow MK, Moutsopoulos HM, Mavragani CP.

Sci Rep. 2017 Aug 4;7(1):7354. doi: 10.1038/s41598-017-07347-w.

5.

Reactive oxygen species induce virus-independent MAVS oligomerization in systemic lupus erythematosus.

Buskiewicz IA, Montgomery T, Yasewicz EC, Huber SA, Murphy MP, Hartley RC, Kelly R, Crow MK, Perl A, Budd RC, Koenig A.

Sci Signal. 2016 Nov 29;9(456):ra115. Erratum in: Sci Signal. 2017 May 16;10 (479):.

6.

Expression of Long Interspersed Nuclear Element 1 Retroelements and Induction of Type I Interferon in Patients With Systemic Autoimmune Disease.

Mavragani CP, Sagalovskiy I, Guo Q, Nezos A, Kapsogeorgou EK, Lu P, Liang Zhou J, Kirou KA, Seshan SV, Moutsopoulos HM, Crow MK.

Arthritis Rheumatol. 2016 Nov;68(11):2686-2696. doi: 10.1002/art.39795.

7.

The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016.

Winthrop KL, Strand V, van der Heijde DM, Mease PJ, Crow MK, Weinblatt M, Bathon JM, Buch MH, Burmester GR, Dougados M, Kay J, Mariette X, Breedveld FC, Kalden JR, Smolen JS, Furst DE.

Clin Exp Rheumatol. 2016 Jul-Aug;34(4 Suppl 98):69-76. Epub 2016 Aug 3.

8.

Novel molecular signatures in mononuclear cell populations from patients with systemic lupus erythematosus.

Olferiev M, Jacek E, Kirou KA, Crow MK.

Clin Immunol. 2016 Nov;172:34-43. doi: 10.1016/j.clim.2016.08.018. Epub 2016 Aug 26.

PMID:
27576056
9.

Autoimmunity: Interferon α or β: which is the culprit in autoimmune disease?

Crow MK.

Nat Rev Rheumatol. 2016 Aug;12(8):439-40. doi: 10.1038/nrrheum.2016.117. Epub 2016 Jul 14. No abstract available.

PMID:
27411904
10.

Systemic lupus erythematosus.

Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, Ruiz-Irastorza G, Hughes G.

Nat Rev Dis Primers. 2016 Jun 16;2:16039. doi: 10.1038/nrdp.2016.39. Review.

PMID:
27306639
11.

Autoantibody Specificities and Type I Interferon Pathway Activation in Idiopathic Inflammatory Myopathies.

Ekholm L, Vosslamber S, Tjärnlund A, de Jong TD, Betteridge Z, McHugh N, Plestilova L, Klein M, Padyukov L, Voskuyl AE, Bultink IE, Michiel Pegtel D, Mavragani CP, Crow MK, Vencovsky J, Lundberg IE, Verweij CL.

Scand J Immunol. 2016 Aug;84(2):100-9. doi: 10.1111/sji.12449.

12.

Identification of Candidate Predictors of Lupus Flare.

Crow MK, Olferiev M, Kirou KA.

Trans Am Clin Climatol Assoc. 2015;126:184-96. Review.

13.

Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial.

Gordon JK, Martyanov V, Magro C, Wildman HF, Wood TA, Huang WT, Crow MK, Whitfield ML, Spiera RF.

Arthritis Res Ther. 2015 Aug 18;17:213. doi: 10.1186/s13075-015-0721-3.

14.

Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis.

Nezos A, Gravani F, Tassidou A, Kapsogeorgou EK, Voulgarelis M, Koutsilieris M, Crow MK, Mavragani CP.

J Autoimmun. 2015 Sep;63:47-58. doi: 10.1016/j.jaut.2015.07.002. Epub 2015 Jul 14.

15.

Interferon-α and angiogenic dysregulation in pregnant lupus patients who develop preeclampsia.

Andrade D, Kim M, Blanco LP, Karumanchi SA, Koo GC, Redecha P, Kirou K, Alvarez AM, Mulla MJ, Crow MK, Abrahams VM, Kaplan MJ, Salmon JE.

Arthritis Rheumatol. 2015 Apr;67(4):977-87. doi: 10.1002/art.39029.

16.

Targeting of type I interferon in systemic autoimmune diseases.

Crow MK, Olferiev M, Kirou KA.

Transl Res. 2015 Feb;165(2):296-305. doi: 10.1016/j.trsl.2014.10.005. Epub 2014 Oct 16. Review.

17.

Imatinib mesylate (Gleevec™) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial.

Gordon J, Udeh U, Doobay K, Magro C, Wildman H, Davids M, Mersten JN, Huang WT, Lyman S, Crow MK, Spiera RF.

Clin Exp Rheumatol. 2014 Nov-Dec;32(6 Suppl 86):S-189-93. Epub 2014 Aug 15.

PMID:
25152211
18.

Advances in understanding the role of type I interferons in systemic lupus erythematosus.

Crow MK.

Curr Opin Rheumatol. 2014 Sep;26(5):467-74. doi: 10.1097/BOR.0000000000000087. Review.

19.

Type I interferon in the pathogenesis of lupus.

Crow MK.

J Immunol. 2014 Jun 15;192(12):5459-68. doi: 10.4049/jimmunol.1002795. Review.

20.

Measuring interferon alpha and other cytokines in SLE.

Olferiev M, Lliguicota M, Kirou KA, Crow MK.

Methods Mol Biol. 2014;1134:131-50. doi: 10.1007/978-1-4939-0326-9_10.

PMID:
24497359
21.

A surge in anti-dsDNA titer predicts a severe lupus flare within six months.

Pan N, Amigues I, Lyman S, Duculan R, Aziz F, Crow MK, Kirou KA.

Lupus. 2014 Mar;23(3):293-8. doi: 10.1177/0961203313515763. Epub 2013 Dec 6.

PMID:
24316605
22.

Increased serum type I interferon activity in organ-specific autoimmune disorders: clinical, imaging, and serological associations.

Mavragani CP, Niewold TB, Chatzigeorgiou A, Danielides S, Thomas D, Kirou KA, Kamper E, Kaltsas G, Crow MK.

Front Immunol. 2013 Aug 19;4:238. doi: 10.3389/fimmu.2013.00238. eCollection 2013.

23.

Proteomic analysis of synovial fluid from the osteoarthritic knee: comparison with transcriptome analyses of joint tissues.

Ritter SY, Subbaiah R, Bebek G, Crish J, Scanzello CR, Krastins B, Sarracino D, Lopez MF, Crow MK, Aigner T, Goldring MB, Goldring SR, Lee DM, Gobezie R, Aliprantis AO.

Arthritis Rheum. 2013 Apr;65(4):981-92. doi: 10.1002/art.37823.

24.

Increased IFNα activity and differential antibody response in patients with a history of Lyme disease and persistent cognitive deficits.

Jacek E, Fallon BA, Chandra A, Crow MK, Wormser GP, Alaedini A.

J Neuroimmunol. 2013 Feb 15;255(1-2):85-91. doi: 10.1016/j.jneuroim.2012.10.011. Epub 2012 Nov 8.

25.

Sarcoidosis triggered by interferon-Beta treatment of multiple sclerosis: a case report and focused literature review.

Chakravarty SD, Harris ME, Schreiner AM, Crow MK.

Semin Arthritis Rheum. 2012 Oct;42(2):206-12. doi: 10.1016/j.semarthrit.2012.03.008. Epub 2012 May 8. Review.

PMID:
22572392
26.

Synovial fluid from patients with early osteoarthritis modulates fibroblast-like synoviocyte responses to toll-like receptor 4 and toll-like receptor 2 ligands via soluble CD14.

Nair A, Kanda V, Bush-Joseph C, Verma N, Chubinskaya S, Mikecz K, Glant TT, Malfait AM, Crow MK, Spear GT, Finnegan A, Scanzello CR.

Arthritis Rheum. 2012 Jul;64(7):2268-77. doi: 10.1002/art.34495.

27.

IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus.

Niewold TB, Kelly JA, Kariuki SN, Franek BS, Kumar AA, Kaufman KM, Thomas K, Walker D, Kamp S, Frost JM, Wong AK, Merrill JT, Alarcón-Riquelme ME, Tikly M, Ramsey-Goldman R, Reveille JD, Petri MA, Edberg JC, Kimberly RP, Alarcón GS, Kamen DL, Gilkeson GS, Vyse TJ, James JA, Gaffney PM, Moser KL, Crow MK, Harley JB.

Ann Rheum Dis. 2012 Mar;71(3):463-8. doi: 10.1136/annrheumdis-2011-200463. Epub 2011 Nov 16.

28.

Identification of a central role for complement in osteoarthritis.

Wang Q, Rozelle AL, Lepus CM, Scanzello CR, Song JJ, Larsen DM, Crish JF, Bebek G, Ritter SY, Lindstrom TM, Hwang I, Wong HH, Punzi L, Encarnacion A, Shamloo M, Goodman SB, Wyss-Coray T, Goldring SR, Banda NK, Thurman JM, Gobezie R, Crow MK, Holers VM, Lee DM, Robinson WH.

Nat Med. 2011 Nov 6;17(12):1674-9. doi: 10.1038/nm.2543.

29.

Felty's syndrome autoantibodies bind to deiminated histones and neutrophil extracellular chromatin traps.

Dwivedi N, Upadhyay J, Neeli I, Khan S, Pattanaik D, Myers L, Kirou KA, Hellmich B, Knuckley B, Thompson PR, Crow MK, Mikuls TR, Csernok E, Radic M.

Arthritis Rheum. 2012 Apr;64(4):982-92. doi: 10.1002/art.33432. Epub 2011 Oct 27.

30.

Autoimmune disease risk variant of IFIH1 is associated with increased sensitivity to IFN-α and serologic autoimmunity in lupus patients.

Robinson T, Kariuki SN, Franek BS, Kumabe M, Kumar AA, Badaracco M, Mikolaitis RA, Guerrero G, Utset TO, Drevlow BE, Zaacks LS, Grober JS, Cohen LM, Kirou KA, Crow MK, Jolly M, Niewold TB.

J Immunol. 2011 Aug 1;187(3):1298-303. doi: 10.4049/jimmunol.1100857. Epub 2011 Jun 24.

31.

Degos disease: a C5b-9/interferon-α-mediated endotheliopathy syndrome.

Magro CM, Poe JC, Kim C, Shapiro L, Nuovo G, Crow MK, Crow YJ.

Am J Clin Pathol. 2011 Apr;135(4):599-610. doi: 10.1309/AJCP66QIMFARLZKI.

PMID:
21411783
32.

Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial.

Spiera RF, Gordon JK, Mersten JN, Magro CM, Mehta M, Wildman HF, Kloiber S, Kirou KA, Lyman S, Crow MK.

Ann Rheum Dis. 2011 Jun;70(6):1003-9. doi: 10.1136/ard.2010.143974. Epub 2011 Mar 11.

33.

Type I interferon in organ-targeted autoimmune and inflammatory diseases.

Crow MK.

Arthritis Res Ther. 2010;12 Suppl 1:S5. doi: 10.1186/ar2886. Epub 2010 Aug 25. Review.

34.

A 26-year-old white man with a systemic lupus erythematosus flare and acute multiorgan ischemia: Vasculitis or thrombosis?

Cherian J, Duculan R, Amigues I, Crow MK, Kirou KA.

Arthritis Care Res (Hoboken). 2011 May;63(5):766-74. doi: 10.1002/acr.20439. No abstract available.

35.

Synovial inflammation in patients undergoing arthroscopic meniscectomy: molecular characterization and relationship to symptoms.

Scanzello CR, McKeon B, Swaim BH, DiCarlo E, Asomugha EU, Kanda V, Nair A, Lee DM, Richmond JC, Katz JN, Crow MK, Goldring SR.

Arthritis Rheum. 2011 Feb;63(2):391-400. doi: 10.1002/art.30137.

36.

A loss-of-function variant of the antiviral molecule MAVS is associated with a subset of systemic lupus patients.

Pothlichet J, Niewold TB, Vitour D, Solhonne B, Crow MK, Si-Tahar M.

EMBO Mol Med. 2011 Mar;3(3):142-52. doi: 10.1002/emmm.201000120. Epub 2011 Jan 26.

37.

Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients.

Thurlings RM, Boumans M, Tekstra J, van Roon JA, Vos K, van Westing DM, van Baarsen LG, Bos C, Kirou KA, Gerlag DM, Crow MK, Bijlsma JW, Verweij CL, Tak PP.

Arthritis Rheum. 2010 Dec;62(12):3607-14. doi: 10.1002/art.27702.

38.

Activation of the type I interferon pathway in primary Sjogren's syndrome.

Mavragani CP, Crow MK.

J Autoimmun. 2010 Nov;35(3):225-31. doi: 10.1016/j.jaut.2010.06.012. Epub 2010 Jul 31. Review.

PMID:
20674271
39.

Trait-stratified genome-wide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosus.

Kariuki SN, Franek BS, Kumar AA, Arrington J, Mikolaitis RA, Utset TO, Jolly M, Crow MK, Skol AD, Niewold TB.

Arthritis Res Ther. 2010;12(4):R151. doi: 10.1186/ar3101. Epub 2010 Jul 26.

40.

Anti-neural antibody reactivity in patients with a history of Lyme borreliosis and persistent symptoms.

Chandra A, Wormser GP, Klempner MS, Trevino RP, Crow MK, Latov N, Alaedini A.

Brain Behav Immun. 2010 Aug;24(6):1018-24. doi: 10.1016/j.bbi.2010.03.002. Epub 2010 Mar 18.

41.

Interferon-alpha: a therapeutic target in systemic lupus erythematosus.

Crow MK.

Rheum Dis Clin North Am. 2010 Feb;36(1):173-86, x. doi: 10.1016/j.rdc.2009.12.008.

42.

Relationship of asymmetric dimethylarginine and homocysteine to vascular aging in systemic lupus erythematosus patients.

Perna M, Roman MJ, Alpert DR, Crow MK, Lockshin MD, Sammaritano L, Devereux RB, Cooke JP, Salmon JE.

Arthritis Rheum. 2010 Jun;62(6):1718-22. doi: 10.1002/art.27392.

44.

Long interspersed nuclear elements (LINE-1): potential triggers of systemic autoimmune disease.

Crow MK.

Autoimmunity. 2010 Feb;43(1):7-16. doi: 10.3109/08916930903374865. Review.

PMID:
19961365
45.

Developments in the clinical understanding of lupus.

Crow MK.

Arthritis Res Ther. 2009;11(5):245. doi: 10.1186/ar2762. Epub 2009 Oct 14. Review.

46.

Age- and gender-specific modulation of serum osteopontin and interferon-alpha by osteopontin genotype in systemic lupus erythematosus.

Kariuki SN, Moore JG, Kirou KA, Crow MK, Utset TO, Niewold TB.

Genes Immun. 2009 Jul;10(5):487-94. doi: 10.1038/gene.2009.15. Epub 2009 Apr 2.

47.

Local cytokine profiles in knee osteoarthritis: elevated synovial fluid interleukin-15 differentiates early from end-stage disease.

Scanzello CR, Umoh E, Pessler F, Diaz-Torne C, Miles T, Dicarlo E, Potter HG, Mandl L, Marx R, Rodeo S, Goldring SR, Crow MK.

Osteoarthritis Cartilage. 2009 Aug;17(8):1040-8. doi: 10.1016/j.joca.2009.02.011. Epub 2009 Mar 6.

48.

Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation.

Fernandez DR, Telarico T, Bonilla E, Li Q, Banerjee S, Middleton FA, Phillips PE, Crow MK, Oess S, Muller-Esterl W, Perl A.

J Immunol. 2009 Feb 15;182(4):2063-73. doi: 10.4049/jimmunol.0803600.

49.

Interferon-induced versus chemokine transcripts as lupus biomarkers.

Crow MK, Kirou KA.

Arthritis Res Ther. 2008;10(6):126. doi: 10.1186/ar2559. Epub 2008 Dec 18.

50.

Independent association of rheumatoid arthritis with increased left ventricular mass but not with reduced ejection fraction.

Rudominer RL, Roman MJ, Devereux RB, Paget SA, Schwartz JE, Lockshin MD, Crow MK, Sammaritano L, Levine DM, Salmon JE.

Arthritis Rheum. 2009 Jan;60(1):22-9. doi: 10.1002/art.24148.

Supplemental Content

Support Center